rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - daganatellenes szerek - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
genotropin 5,3 mg por és oldószer oldatos injekcióhoz
pfizer kft. - a szomatropin (hgh) -
solu-medrol 40 mg por és oldószer oldatos injekcióhoz
pfizer kft. - metilprednizolon -
solu-medrol 125 mg por és oldószer oldatos injekcióhoz
pfizer kft. - metilprednizolon -
solu-medrol 250 mg por és oldószer oldatos injekcióhoz
pfizer kft. - metilprednizolon -
genotropin 12 mg por és oldószer oldatos injekcióhoz
pfizer kft. - a szomatropin (hgh) -
aminomix 1 novum oldatos infúzió
fresenius kabi deutschland gmbh - electrolits; aminosavak -
aminomix 2 novum oldatos infúzió
fresenius kabi deutschland gmbh - electrolits; aminosavak -
phoxil 1,2 mmol/l foszfát hemodializáló vagy hemofiltrációs oldat
baxter holding bv - electrolits - hemofiltrates